Abstract
A study cohort is a group of individuals with common characteristics who are initially defined, composed and then examined or tracked over a given time period. In a clinical trial, outlining the study cohort begins with clearly defined, study-specific eligibility criteria. Inclusion criteria and exclusion criteria together determine who is eligible to participate in the study. These selection or eligibility criteria are determined during the planning phase of the study, with the study goals of the clinical trial in mind. Establishing eligibility criteria primarily requires the precise definition of the primary and secondary study outcomes, which provides guidance for the sample size of the clinical trial that is required to detect a significant difference between the study intervention and control group. The eligibility criteria should be sufficiently narrow to ensure internal study validity, but sufficiently broad to allow for generalizability of the study results to the general population. In addition, eligibility criteria must be chosen carefully to allow for the feasible recruitment of study subjects into the clinical trial and must meet ethical criteria established by the National Institutes of Health (NIH).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
ClinicalTrials.gov. Learn about clinical studies. https://clinicaltrials.gov/ct2/about-studies/learn. Accessed 25 July 2019.
Underwood RT. Basic design considerations. In: Chow S-C, Liu J-P, editors. Design and analysis of clinical trials: concepts and methodologies. 3rd ed. New York: John Wiley & Sons; 2014. p. 85–115.
Kim ES, Bernstein D, Hilsenbeck SG, et al. Modernizing eligibility criteria for molecularly driven trials. J Clin Oncol. 2015;33(25):2815–20.
Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233–40.
Brody T. Inclusion/exclusion criteria, stratification, and subgroups—part I. In: Brody T, editor. Clinical trials. 2nd ed. Amsterdam: Elsevier; 2016. p. 83–113.
Chin RY, Lee BY. Patient selection and sampling: key components of clinical trials and programs. In: Principles and practice of clinical trial medicine. Boston: Academic; 2008.
Nottage M, Siu LL. Principles of clinical trial design. J Clin Oncol. 2002;20(18 Suppl):42S–6S.
Szklo M. Population-based cohort studies. Epidemiol Rev. 1998;20(1):81–90.
Ellimoottil C, Vijan S, Flanigan RC. A primer on clinical trial design. Urol Oncol Semin Orig Investig. 2015;33(3):116–21.
Stock E, Biswas K. Sample size calculation. In: Itani KMF, Reda D, editors. Clinical trials design in operative and non operative invasive procedures. New York: Springer International Publishing; 2017. p. 141–50.
Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials. J Am Coll Cardiol. 2015;66(24):2757–66.
Browner W, Newman T, Cummings S, Hulley S. Estimating sample size and power. In: Hulley S, Cummings S, Browner W, Grady D, Hearst N, Newman T, editors. Designing clinical research: an epidemiologic approach. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. p. 65–84.
Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. Lancet. 2005;365(9467):1348–53.
Kirby A, Gebski V, Keech AC. Determining the sample size in a clinical trial. Med J Aust. 2002;177(5):256–7.
Caldwell PHY, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.
Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2(2):MR000013.
Itani KMF, Reda DJ. Clinical trials design in operative and nonoperative invasive procedures. Clin Trials Des Oper Non Oper Invasive Proced. 2017;112:1–495.
Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria—balancing patient protection and participation in oncology trials. N Engl J Med. 2017;376(16):1504–5.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. http://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/#. Published 1979. Accessed 25 July 2019.
U.S. Department of Health and Human Services. National Institutes of Health. NIH policy and guidelines on the inclusion of women and minorities as participants in research involving human subjects. https://grants.nih.gov/policy/inclusion/women-and-minorities.htm. Accessed 25 July 2019.
National Institutes of Health. Guidelines for the review of inclusion on the basis of sex/gender, race, ethnicity, and age in clinical research. https://grants.nih.gov/grants/peer/guidelines_general/Review_Human_subjects_Inclusion.pdf. Accessed 25 July 2019.
U.S. Department of Health and Human Services. National Institutes of Health. NIH policy and guidelines on the inclusion of individuals across the lifespan as participants in research involving human subjects. https://grants.nih.gov/policy/inclusion/lifespan.htm. Accessed 25 July 2019.
Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational newdrug applications in 2015. J Clin Oncol. 2017;35(33):3745–52.
Penel N, Lebellec L, Vanseymortier M. Reappraisal of eligibility criteria in cancer clinical trials. Curr Opin Oncol. 2018;30(5):352–7.
Lichtman SM, Harvey RD, Damiette Smit M-A, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer research organ dysfunction, prior or concurrent malignancy, and Comorbidities Working Group. J Clin Oncol. 2017;35(33):3753–9.
Gore L, Ivy SP, Balis FM, et al. Modernizing clinical trial eligibility: recommendations of the American Society of Clinical Oncology-friends of Cancer research minimum age working group. J Clin Oncol. 2017;35(33):3781–7.
Uldrick TS, Ison G, Rudek MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-friends of Cancer research HIV working group. J Clin Oncol. 2017;35(33):3774–80.
Lin NU, Prowell T, Tan AR, et al. Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-friends of Cancer research brain metastases working group. J Clin Oncol. 2017;35(33):3760–73.
Moher D, Schulz KF, Altman D. CONSORT group (consolidated standards of reporting trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA. 2001;285(15):1987–91.
Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996;276(8):637–9.
The CONSORT statement. http://www.consort-statement.org/. Accessed 25 July 2019.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Keung, E.Z., McElroy, L.M., Ladner, D.P., Grubbs, E.G. (2020). Defining the Study Cohort: Inclusion and Exclusion Criteria. In: Pawlik, T., Sosa, J. (eds) Clinical Trials. Success in Academic Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-35488-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-030-35488-6_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35487-9
Online ISBN: 978-3-030-35488-6
eBook Packages: MedicineMedicine (R0)